Circulating semicarbazide-sensitive amine oxidase is raised both in Type I (insulin-dependent), in Type II (non-insulin-dependent) diabetes mellitus and even in childhood Type I diabetes at first clinical diagnosis

Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus

“…It is not yet known which factors are involved in the regulation. However, circulating SSAO has been found to be elevated in type 1 and type 2 diabetes [10][11][12][13], in the former already at the time of diagnosis. The mechanism behind the elevation of plasma SSAO in diabetes is not known.…”

Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia

“…In a cross-sectional study, we have demonstrated that T1DM is associated with higher plasma SSAO activity, 22 in which SSAO activity was higher in newly diagnosed T1DM (n = 100), compared to their siblings (n = 76), but did not correlate with HbA1c levels. In another article by Boomsma et al, 21 plasma SSAO activity in T1DM (n = 104) with microvascular complications was increased relative to controls and correlated with renal function and with HbA1c.…”

“…Similarly in T2DM, circulating SSAO activity has been reported to be increased relative to control subjects [21][22][23] and has been found to be higher in T2DM subjects with proliferative diabetic retinopathy and/or clinically significant macular oedema. 23 Positive correlations have been described with HbA1c, 14 adiposity and dyslipidaemia.…”

“…13,19,20 Most human data regarding SSAO activity in diabetes relate to type 2 diabetes (T2DM), with few studies in type 1 diabetes (T1DM). 21,22 The levels of SSAO activity, its clinical correlates, regulatory factors and role of SSAO/VAP-1 activity in diabetes complications require further elucidation. 7,[22][23][24] Circulating SSAO activity is increased in diabetes, both in humans 22 and animals, 25 in renal disease, 26 cardiovascular disease (CVD), 12 inflammation 27 and in disseminated cancer.…”

“…21,22 The levels of SSAO activity, its clinical correlates, regulatory factors and role of SSAO/VAP-1 activity in diabetes complications require further elucidation. 7,[22][23][24] Circulating SSAO activity is increased in diabetes, both in humans 22 and animals, 25 in renal disease, 26 cardiovascular disease (CVD), 12 inflammation 27 and in disseminated cancer. 28 Elevated adrenaline output, 29 which is associated with increased CVD-related morbidity and mortality, 30 may also upregulate SSAO activity.…”